Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
Mayne Pharma Group has released an investor presentation detailing the U.S. launch of its DistributeRx business, highlighting this new commercial initiative as part of its specialty pharmaceuticals strategy. The company is also hosting an investor webinar featuring its CEO and DistributeRx leadership to brief investors and take questions, signaling a push to engage the market and clarify the strategic role of DistributeRx in its growth plans.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an ASX-listed specialty pharmaceutical company that focuses on commercialising novel medicines to offer patients safer, more accessible treatments. The company is a leader in dermatology and women’s health in the U.S. and also provides contract development and manufacturing services globally, underpinned by a 40-year track record in oral drug delivery innovation.
Average Trading Volume: 453,005
Technical Sentiment Signal: Sell
Current Market Cap: A$190.1M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.